Members

Zhongsheng You Photo

Zhongsheng You, PhD

My lab studies the molecular mechanisms of genome maintenance in human cells. A major focus of our current work is to further dissect this novel signaling pathway, in particular, the ion channel(s) and signal transducers responsible for Ca2+ induction after replication stress for genome protection.

Learn more
jieya-shao

Jieya Shao, PhD

My lab is broadly interested in uncovering novel and clinically relevant drivers and targets of cancer with the overarching goal of improving patient outcome. Our current major research effort is focused on understanding the mechanisms of action and therapeutic potentials of two multi-functional proteins (the actin-binding protein Profilin-1 and the AAA+ ATPase p97/VCP) in the contexts of genome stability maintenance and chemotherapy efficacy.

Learn more
susana-gonzalo

Susana Gonzalo, PhD

My lab focuses on three areas of research: 1) Uncovering essential roles for lamins in DNA repair, DNA replication, and telomere structure, length and function; 2) Identifying new mechanisms underlying Hutchinson Gilford Progeria Syndrome (HGPS) pathology; and 3) Defining the relationship between lamins loss and oncogenic mechanisms, particularly in cancers with poor prognoses such as BRCA-mutated and triple negative breast cancers.

Learn more
Michael Goldstein

Michael Goldstein, MD, PhD

My lab investigates epigenetic mechanisms of cellular responses to radiation- and chemotherapy-induced DNA damage in pediatric and adult tumors of the Central Nervous System as well as HPV-induced tumors. The primary goal of the lab is to identify new molecular pathways that can be pharmacologically targeted to improve tumor response to treatment with radiation and chemotherapy.

Learn more
Katherine Fuh

Katherine Fuh, MD, PhD

My lab focuses on developing new strategies for overcoming treatment resistance and preventing metastasis for ovarian and uterine cancers within the context of the tumor microenvironment. To do this, we utilize primary cells cultured from the omentum to re-create the microenvinroment and utilize this model system to improve treatment in parp inhibitors, carboplatin, paclitaxel, and immunotherapy.

Learn more
Mary Mullen

Mary Mullen, MD

My lab’s current goal is to identify a biomarker predictive of tumor sensitivity to DNA damaging agents and to identify kinases and deubiquitinases involved in ovarian cancer resistance to DNA damaging agents. My lab is also focused on utilizing RAD51, a protein involved in homologous recombination, to create a functional biomarker for homologous recombination deficiencies. We hope to use this information to develop personalized treatment strategies for ovarian cancer which will minimize toxicity and optimize efficacy.

Learn more
Jeff-Bednarski

Jeffrey Bednarski, MD, PhD

My lab investigates signaling networks that regulate hematopoiesis and lymphopoiesis and how alterations in these pathways lead to immune deficiencies or transformation into lymphoid malignancy. In particular, we’re interested in how signals from DNA damage cooperate with other developmental processes to direct hematopoietic cell differentiation and survival. We’re also interested in understanding how errors in DNA damage responses lead to aberrant immune development and immune deficiencies.

Learn more